Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytosorbents (CTSO) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to -$64000.0.

  • Cytosorbents' Other Non Operating Income fell 10241.51% to -$64000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year increase of 2555.92%. This contributed to the annual value of -$4.2 million for FY2024, which is 31673.49% down from last year.
  • According to the latest figures from Q3 2025, Cytosorbents' Other Non Operating Income is -$64000.0, which was down 10241.51% from $6.2 million recorded in Q2 2025.
  • In the past 5 years, Cytosorbents' Other Non Operating Income ranged from a high of $6.2 million in Q2 2025 and a low of -$4.9 million during Q4 2024
  • Moreover, its 5-year median value for Other Non Operating Income was -$493488.0 (2021), whereas its average is $96122.9.
  • In the last 5 years, Cytosorbents' Other Non Operating Income plummeted by 117760.44% in 2022 and then skyrocketed by 123566.18% in 2025.
  • Cytosorbents' Other Non Operating Income (Quarter) stood at -$493488.0 in 2021, then surged by 1015.53% to $4.5 million in 2022, then crashed by 40.61% to $2.7 million in 2023, then crashed by 282.79% to -$4.9 million in 2024, then skyrocketed by 98.7% to -$64000.0 in 2025.
  • Its Other Non Operating Income stands at -$64000.0 for Q3 2025, versus $6.2 million for Q2 2025 and $3.0 million for Q1 2025.